ES458691A1 - Procedimiento para preparar polipeptidos. - Google Patents

Procedimiento para preparar polipeptidos.

Info

Publication number
ES458691A1
ES458691A1 ES458691A ES458691A ES458691A1 ES 458691 A1 ES458691 A1 ES 458691A1 ES 458691 A ES458691 A ES 458691A ES 458691 A ES458691 A ES 458691A ES 458691 A1 ES458691 A1 ES 458691A1
Authority
ES
Spain
Prior art keywords
substitution
luliberine
luteinizing hormone
azaglycine
alpha
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES458691A
Other languages
English (en)
Spanish (es)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Imperial Chemical Industries Ltd
Original Assignee
Imperial Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imperial Chemical Industries Ltd filed Critical Imperial Chemical Industries Ltd
Publication of ES458691A1 publication Critical patent/ES458691A1/es
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06086—Dipeptides with the first amino acid being basic
    • C07K5/06095—Arg-amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/23—Luteinising hormone-releasing hormone [LHRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/13—Luteinizing hormone-releasing hormone; related peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Reproductive Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Fodder In General (AREA)
  • Medicines Containing Plant Substances (AREA)
ES458691A 1976-05-11 1977-05-11 Procedimiento para preparar polipeptidos. Expired ES458691A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB19327/76A GB1524747A (en) 1976-05-11 1976-05-11 Polypeptide

Publications (1)

Publication Number Publication Date
ES458691A1 true ES458691A1 (es) 1978-08-16

Family

ID=10127509

Family Applications (1)

Application Number Title Priority Date Filing Date
ES458691A Expired ES458691A1 (es) 1976-05-11 1977-05-11 Procedimiento para preparar polipeptidos.

Country Status (27)

Country Link
US (1) US4100274A (OSRAM)
JP (1) JPS52136172A (OSRAM)
AT (2) AT379400B (OSRAM)
AU (1) AU508025B2 (OSRAM)
BE (1) BE854467A (OSRAM)
BG (1) BG60740B2 (OSRAM)
CA (1) CA1101844A (OSRAM)
CH (2) CH627151A5 (OSRAM)
CS (1) CS199673B2 (OSRAM)
DD (1) DD136738A5 (OSRAM)
DE (1) DE2720245C2 (OSRAM)
DK (1) DK149596C (OSRAM)
ES (1) ES458691A1 (OSRAM)
FI (1) FI64139C (OSRAM)
FR (1) FR2351092A1 (OSRAM)
GB (1) GB1524747A (OSRAM)
HU (1) HU179990B (OSRAM)
IE (1) IE44426B1 (OSRAM)
IL (1) IL52014A (OSRAM)
NL (2) NL191793C (OSRAM)
NO (2) NO147304C (OSRAM)
NZ (1) NZ183931A (OSRAM)
PL (2) PL104362B1 (OSRAM)
SE (2) SE437837B (OSRAM)
SU (1) SU910116A3 (OSRAM)
YU (1) YU40672B (OSRAM)
ZA (1) ZA772433B (OSRAM)

Families Citing this family (139)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4234571A (en) * 1979-06-11 1980-11-18 Syntex (U.S.A.) Inc. Nonapeptide and decapeptide derivatives of luteinizing hormone releasing hormone
DE3411224A1 (de) * 1984-03-27 1985-10-10 Hoechst Ag, 6230 Frankfurt Verfahren zur racematarmen herstellung von peptidzwischenprodukten der gonadorelin- und gonadorelinanaloga-synthese und neue zwischenprodukte bei diesem verfahren
US4760053A (en) * 1984-08-02 1988-07-26 Fernand Labrie Combination therapy for selected sex steroid dependent cancers
US4666885A (en) * 1985-02-08 1987-05-19 Fernand Labrie Combination therapy for treatment of female breast cancer
US4705778A (en) * 1985-10-22 1987-11-10 Sri International Orally active LHRH analogs
JPH0284272U (OSRAM) * 1988-12-20 1990-06-29
JP2672677B2 (ja) * 1989-02-09 1997-11-05 タツプ・フアーマシユーテイカルズ・インコーポレイテツド Ｌｈｒｈ同族体
US5372996A (en) * 1989-03-10 1994-12-13 Endorecherche, Inc. Method of treatment of androgen-related diseases
AU5281990A (en) * 1989-03-10 1990-10-09 Endorecherche Inc. Combination therapy for treatment of estrogen sensitive diseases
CA2063378A1 (en) * 1989-07-07 1991-01-08 Fernand Labrie Androgen derivatives for use in the inhibition of sex steroid activity
JP3350048B2 (ja) * 1989-07-07 2002-11-25 アンドルシェルシュ・インコーポレイテッド アンドロゲン関連疾患の治療方法
GB9112859D0 (en) * 1991-06-14 1991-07-31 Ici Plc Peptide process
CZ286894A3 (en) * 1992-05-21 1995-09-13 Endorecherche Inc Pharmaceutical preparation
US7833543B2 (en) * 1995-06-07 2010-11-16 Durect Corporation High viscosity liquid controlled delivery system and medical or surgical device
US6413536B1 (en) 1995-06-07 2002-07-02 Southern Biosystems, Inc. High viscosity liquid controlled delivery system and medical or surgical device
CA2192773C (en) 1995-12-15 2008-09-23 Hiroaki Okada Production of sustained-release preparation for injection
CA2192782C (en) 1995-12-15 2008-10-14 Nobuyuki Takechi Production of microspheres
WO1999007874A1 (en) * 1996-06-13 1999-02-18 Itoham Foods Inc. Process for producing lh-rh derivatives
US20060025328A1 (en) * 1997-05-28 2006-02-02 Burns Patrick J Compositions suitable for controlled release of the hormone GnRH and its analogs
US6051558A (en) * 1997-05-28 2000-04-18 Southern Biosystems, Inc. Compositions suitable for controlled release of the hormone GnRH and its analogs
US6242421B1 (en) 1997-11-06 2001-06-05 Richard Lloyd Bowen Methods for preventing and treating Alzheimer's disease
US6858598B1 (en) 1998-12-23 2005-02-22 G. D. Searle & Co. Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US6833373B1 (en) 1998-12-23 2004-12-21 G.D. Searle & Co. Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US20070274946A1 (en) * 1999-04-15 2007-11-29 Norwood Immunoloty, Ltd. Tolerance to Graft Prior to Thymic Reactivation
US20040258672A1 (en) * 1999-04-15 2004-12-23 Monash University Graft acceptance through manipulation of thymic regeneration
US20040265285A1 (en) * 1999-04-15 2004-12-30 Monash University Normalization of defective T cell responsiveness through manipulation of thymic regeneration
US20040259803A1 (en) * 1999-04-15 2004-12-23 Monash University Disease prevention by reactivation of the thymus
AUPR074500A0 (en) * 2000-10-13 2000-11-09 Monash University Treatment of t cell disorders
US20040241842A1 (en) * 1999-04-15 2004-12-02 Monash University Stimulation of thymus for vaccination development
US20050020524A1 (en) * 1999-04-15 2005-01-27 Monash University Hematopoietic stem cell gene therapy
ES2154590B1 (es) 1999-05-20 2001-11-01 Lipotec Sa Procedimiento de sintesis de peptidos en fase solida
AR023940A1 (es) 2000-05-03 2002-09-04 Eriochem Sa Procedimiento para la produccion de microcapsulas de liberacion prolongada de peptidos solubles en agua
DE10032256C2 (de) * 2000-07-03 2003-06-05 Infineon Technologies Ag Chip-ID-Register-Anordnung
US20060088512A1 (en) * 2001-10-15 2006-04-27 Monash University Treatment of T cell disorders
ES2640787T3 (es) 2001-02-19 2017-11-06 Novartis Ag Combinación de un derivado de rapamicina y letrozol para tratar el cáncer de mama
BR0209647A (pt) 2001-05-16 2004-07-27 Novartis Ag Combinação que compreende n-{5-[4-(4-metil-piperazino-metil)-benzoilamido]-2-metil fenil}-4-(3-piridil)-2-pirimidina-amina e um agente quimioterapêutico
US20060287282A1 (en) * 2001-06-25 2006-12-21 Steiner Mitchell S Compositions comprising a SARM ad GnRH agonist or a GnRH antagonist, and methods of use thereof
WO2003041739A1 (fr) 2001-11-13 2003-05-22 Takeda Chemical Industries, Ltd. Agents anticancer
GB0128510D0 (en) * 2001-11-28 2002-01-23 Novartis Ag Organic compounds
US20030144203A1 (en) * 2001-12-19 2003-07-31 Voyager Pharmaceutical Corporation Methods for slowing senescence and treating and preventing diseases associated with senescence
GB0206215D0 (en) 2002-03-15 2002-05-01 Novartis Ag Organic compounds
JP5227492B2 (ja) 2002-05-16 2013-07-03 ノバルティス アーゲー 癌におけるｅｄｇレセプター結合剤の使用
US20040001889A1 (en) 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
ATE482695T1 (de) 2002-12-13 2010-10-15 Durect Corp Orale darreichungsform mit flüssigen hochviskosen trägersystemen
BRPI0412259B1 (pt) 2003-07-22 2019-08-20 Astex Therapeutics Limited Compostos de 1H-pirazol 3,4-dissubstituídos como moduladores de quinases dependentes de ciclina (CDK), seus usos, processo para a preparação dos mesmos e composição farmacêutica
GB0320806D0 (en) * 2003-09-05 2003-10-08 Astrazeneca Ab Therapeutic treatment
US20080279812A1 (en) * 2003-12-05 2008-11-13 Norwood Immunology, Ltd. Disease Prevention and Vaccination Prior to Thymic Reactivation
AU2005231956B2 (en) 2004-04-07 2009-11-05 Novartis Ag Inhibitors of IAP
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
US7625869B2 (en) * 2004-06-25 2009-12-01 Takeda Pharmaceutical Company Limited Metastin derivatives and use thereof
JP5285275B2 (ja) * 2004-09-17 2013-09-11 デュレクト コーポレーション 制御されたデリバリーシステム
GB0425854D0 (en) * 2004-11-25 2004-12-29 Astrazeneca Ab Therapeutic treatment
US8404718B2 (en) 2005-01-21 2013-03-26 Astex Therapeutics Limited Combinations of pyrazole kinase inhibitors
RU2436575C2 (ru) * 2005-01-21 2011-12-20 Астекс Терапьютикс Лимитед Соединения для использования в фармацевтике
AU2006207325B2 (en) 2005-01-21 2012-08-16 Astex Therapeutics Limited Pharmaceutical compounds
AR054425A1 (es) 2005-01-21 2007-06-27 Astex Therapeutics Ltd Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico.
DK1773870T3 (da) 2005-05-03 2010-04-12 Novetide Ltd Fremgangsmåder til fremstilling af peptid, der har et C-terminalt amid
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
EP1996550A2 (en) 2005-09-27 2008-12-03 Novartis AG Carboxyamine compounds and their use in the treatment of hdac dependent diseases
GB0605120D0 (en) 2006-03-14 2006-04-26 Novartis Ag Organic Compounds
KR20090007635A (ko) 2006-05-09 2009-01-19 노파르티스 아게 철 킬레이터 및 항-신생물 약제를 포함하는 조합물 및 그의용도
CN101516885A (zh) 2006-09-29 2009-08-26 诺瓦提斯公司 作为pi3k脂质激酶抑制剂的吡唑并嘧啶类化合物
JP5528806B2 (ja) 2006-10-12 2014-06-25 アステックス、セラピューティックス、リミテッド 複合薬剤
EP2073807A1 (en) 2006-10-12 2009-07-01 Astex Therapeutics Limited Pharmaceutical combinations
DK2117521T3 (da) 2006-11-03 2012-09-03 Durect Corp Transdermale indgivelsessystemer omfattende bupivacain
CA2677651A1 (en) 2007-02-15 2008-08-21 Novartis Ag Combinations of therapeutic agents for treating cancer
CA2706658A1 (en) 2007-12-06 2009-06-18 Durect Corporation Methods useful for the treatment of pain, arthritic conditions or inflammation associated with a chronic condition
EP2268612B1 (en) 2008-03-24 2014-08-20 Novartis AG Arylsulfonamide-based matrix metalloprotease inhibitors
KR101252349B1 (ko) 2008-03-26 2013-04-08 노파르티스 아게 데아세틸라제 ｂ의 히드록사메이트-기재 억제제
US20100260844A1 (en) 2008-11-03 2010-10-14 Scicinski Jan J Oral pharmaceutical dosage forms
JP2012510442A (ja) * 2008-11-28 2012-05-10 ノバルティス アーゲー Ｈｓｐ９０阻害剤の組合せ
WO2010083617A1 (en) 2009-01-21 2010-07-29 Oncalis Ag Pyrazolopyrimidines as protein kinase inhibitors
WO2010088335A1 (en) 2009-01-29 2010-08-05 Novartis Ag Substituted benzimidazoles for the treatment of astrocytomas
DK2445903T3 (da) 2009-06-26 2014-06-23 Novartis Ag 1,3-Disubstituerede imidazolidin-2-on-derivater som CYP17-inhibitorer
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
EP2464649A1 (en) 2009-08-12 2012-06-20 Novartis AG Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation
BR112012008061A2 (pt) 2009-08-20 2016-03-01 Novartis Ag compostos de oxima heterocíclica
CN102574785A (zh) 2009-08-26 2012-07-11 诺瓦提斯公司 四取代的杂芳基化合物和它们作为mdm2和/或mdm4调节剂的用途
JP2013504543A (ja) 2009-09-10 2013-02-07 ノバルティス アーゲー 二環ヘテロアリール類のエーテル誘導体
MY156209A (en) 2009-11-04 2016-01-29 Novartis Ag Heterocyclic sulfonamide derivatives useful mek inhibitors
JP2013512215A (ja) 2009-11-25 2013-04-11 ノバルティス アーゲー 二環式ヘテロアリールのベンゼン縮合６員酸素含有ヘテロ環誘導体
EP2509964B1 (en) 2009-12-08 2014-04-30 Novartis AG Heterocyclic sulfonamide derivatives
CU24130B1 (es) 2009-12-22 2015-09-29 Novartis Ag Isoquinolinonas y quinazolinonas sustituidas
US8440693B2 (en) 2009-12-22 2013-05-14 Novartis Ag Substituted isoquinolinones and quinazolinones
KR20140089402A (ko) 2010-06-16 2014-07-14 앙도르쉐르슈 인코포레이티드 에스트로겐-관련 질병의 치료 또는 예방 방법
WO2011157793A1 (en) 2010-06-17 2011-12-22 Novartis Ag Piperidinyl substituted 1,3-dihydro-benzoimidazol-2-ylideneamine derivatives
CN102947274A (zh) 2010-06-17 2013-02-27 诺瓦提斯公司 联苯基取代的1,3-二氢-苯并咪唑-2-亚基胺衍生物
UA112517C2 (uk) 2010-07-06 2016-09-26 Новартіс Аг Тетрагідропіридопіримідинові похідні
CN103108871B (zh) 2010-09-16 2014-09-10 诺华股份有限公司 17α-羟化酶/C17,20-裂合酶抑制剂
JP2014505088A (ja) 2011-02-10 2014-02-27 ノバルティス アーゲー Ｃ−ＭＥＴチロシンキナーゼ阻害剤としての［１，２，４］トリアゾロ［４，３−ｂ］ピリダジン化合物
US20130338152A1 (en) 2011-03-08 2013-12-19 Irm Llc Fluorophenyl bicyclic heteroaryl compounds
AU2012249421B9 (en) 2011-04-28 2015-10-22 Novartis Ag 17alpha-hydroxylase/C17,20-lyase inhibitors
MX365242B (es) 2011-05-16 2019-05-28 Genzyme Corp El uso del antagonista cxcr4: 1,1´-[1,4-fenileno-bis-(metileno)-bi s-1, 4, 8, 11-tetraazaciclotetradecano (plerixaflor) para el tratamiento del síndrome de whim.
CA2838029A1 (en) 2011-06-09 2012-12-13 Novartis Ag Heterocyclic sulfonamide derivatives
US8859586B2 (en) 2011-06-20 2014-10-14 Novartis Ag Cyclohexyl isoquinolinone compounds
WO2012175520A1 (en) 2011-06-20 2012-12-27 Novartis Ag Hydroxy substituted isoquinolinone derivatives
JP2014518256A (ja) 2011-06-27 2014-07-28 ノバルティス アーゲー テトラヒドロ−ピリド−ピリミジン誘導体の固体形態および塩類
MX339302B (es) 2011-09-15 2016-05-19 Novartis Ag 3-(quinolin-6-il-tio)-[1,2,4]-triazolo-[4,3-a]-piridinas 6-sustituidas como cinasas de tirosina.
US8969341B2 (en) 2011-11-29 2015-03-03 Novartis Ag Pyrazolopyrrolidine compounds
WO2013093850A1 (en) 2011-12-22 2013-06-27 Novartis Ag Quinoline derivatives
WO2013093849A1 (en) 2011-12-22 2013-06-27 Novartis Ag Dihydro-benzo-oxazine and dihydro-pyrido-oxazine derivatives
AU2012355615A1 (en) 2011-12-23 2014-07-10 Novartis Ag Compounds for inhibiting the interaction of BCL2 with binding partners
CN104125955A (zh) 2011-12-23 2014-10-29 诺华股份有限公司 用于抑制bcl2与结合配偶体相互作用的化合物
EA201491260A1 (ru) 2011-12-23 2014-11-28 Новартис Аг Соединения и композиции для ингибирования взаимодействия bcl2 с партнерами по связыванию
CA2859867A1 (en) 2011-12-23 2013-06-27 Novartis Ag Compounds for inhibiting the interaction of bcl2 with binding partners
KR20140104047A (ko) 2011-12-23 2014-08-27 노파르티스 아게 Bcl2와 결합 파트너의 상호작용을 억제하기 위한 화합물
US8815926B2 (en) 2012-01-26 2014-08-26 Novartis Ag Substituted pyrrolo[3,4-D]imidazoles for the treatment of MDM2/4 mediated diseases
UY34807A (es) 2012-05-16 2013-12-31 Novartis Ag Derivados monocíclicos de heteroarilcicloalquil- diamina
JP6171003B2 (ja) 2012-05-24 2017-07-26 ノバルティス アーゲー ピロロピロリジノン化合物
US9789193B2 (en) 2012-06-15 2017-10-17 The Brigham And Women's Hospital, Inc. Compositions for treating cancer and methods for making the same
AU2013303824B2 (en) 2012-08-13 2016-03-31 Elanco Tiergesundheit Ag Bicyclic heteroaryl cycloalkyldiamine derivatives as inhibitors of spleen tyrosine kinases (SYK)
DK2903968T3 (en) 2012-10-02 2017-01-30 Gilead Sciences Inc INHIBITORS OF HISTON DEMETHYLASES
TW201422625A (zh) 2012-11-26 2014-06-16 Novartis Ag 二氫－吡啶并－□衍生物之固體形式
EP2948451B1 (en) 2013-01-22 2017-07-12 Novartis AG Substituted purinone compounds
WO2014115080A1 (en) 2013-01-22 2014-07-31 Novartis Ag Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the p53/mdm2 interaction
WO2014128612A1 (en) 2013-02-20 2014-08-28 Novartis Ag Quinazolin-4-one derivatives
EA030451B1 (ru) 2013-02-27 2018-08-31 Эпитерапьютикс Апс Ингибиторы гистондеметилаз
US9572885B2 (en) 2013-03-15 2017-02-21 Durect Corporation Compositions with a rheological modifier to reduce dissolution variability
US20150018376A1 (en) 2013-05-17 2015-01-15 Novartis Ag Pyrimidin-4-yl)oxy)-1h-indole-1-carboxamide derivatives and use thereof
UY35675A (es) 2013-07-24 2015-02-27 Novartis Ag Derivados sustituidos de quinazolin-4-ona
WO2015022664A1 (en) 2013-08-14 2015-02-19 Novartis Ag Compounds and compositions as inhibitors of mek
US9227969B2 (en) 2013-08-14 2016-01-05 Novartis Ag Compounds and compositions as inhibitors of MEK
WO2015022663A1 (en) 2013-08-14 2015-02-19 Novartis Ag Compounds and compositions as inhibitors of mek
KR20160058889A (ko) 2013-09-22 2016-05-25 칼리토르 사이언시즈, 엘엘씨 치환된 아미노피리미딘 화합물 및 이용 방법
CN112535688A (zh) 2014-01-15 2021-03-23 诺华股份有限公司 药物组合
EP3122729A4 (en) 2014-03-28 2017-11-15 Calitor Sciences, LLC Substituted heteroaryl compounds and methods of use
AU2015241022A1 (en) 2014-03-31 2016-10-27 Gilead Sciences, Inc. Inhibitors of histone demethylases
WO2015153345A1 (en) 2014-04-03 2015-10-08 Invictus Oncology Pvt. Ltd. Supramolecular combinatorial therapeutics
BR112017003442A2 (pt) 2014-08-27 2017-11-28 Gilead Sciences Inc compostos e métodos para inibir histona desmetilases
US9938257B2 (en) 2015-09-11 2018-04-10 Calitor Sciences, Llc Substituted heteroaryl compounds and methods of use
MY205229A (en) 2016-07-06 2024-10-08 Durect Corp Oral dosage form with drug composition, barrier layer and drug layer
JP7254076B2 (ja) 2017-11-19 2023-04-07 サンシャイン・レイク・ファーマ・カンパニー・リミテッド 置換ヘテロアリール化合物及び使用方法
US11602534B2 (en) 2017-12-21 2023-03-14 Hefei Institutes Of Physical Science, Chinese Academy Of Sciences Pyrimidine derivative kinase inhibitors
KR102737185B1 (ko) 2018-01-20 2024-12-05 선샤인 레이크 파르마 컴퍼니 리미티드 치환된 아미노피리미딘 화합물 및 이의 사용 방법
AU2020356605A1 (en) 2019-09-26 2022-04-14 S.I.S. Shulov Innovative Science Ltd. Anti-aging compositions and methods of use thereof
WO2021097256A1 (en) 2019-11-14 2021-05-20 Cohbar, Inc. Cxcr4 antagonist peptides
WO2021146215A1 (en) 2020-01-13 2021-07-22 Durect Corporation Sustained release drug delivery systems with reduced impurities and related methods
JP2024503402A (ja) 2021-01-12 2024-01-25 デュレクト コーポレーション 徐放性薬物送達システム及び関連の方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3914412A (en) * 1973-10-11 1975-10-21 Abbott Lab {8 Des{13 Gly{9 {0 10 -Gn{13 RH nonapeptide amide analogs in position 6 having ovulation-inducing activity
US4005063A (en) * 1973-10-11 1977-01-25 Abbott Laboratories [Des-gly]10 -GnRH nonapeptide anide analogs in position 6 having ovulation-inducing activity
US3901872A (en) * 1974-03-13 1975-08-26 American Home Prod P-glu-his-trp-ser-tyr-d-pgl-leu-arg-pro-gly-nh' 2 'and intermediates
JPS50142563A (OSRAM) * 1974-04-26 1975-11-17
US3896104A (en) * 1974-05-22 1975-07-22 American Home Prod P-glu-his-trp-ser-tyr-d-lys-leu-arg-pro-gly-nh' 2 'and intermediates
DE2438350C3 (de) * 1974-08-09 1979-06-13 Hoechst Ag, 6000 Frankfurt Peptide mit starker LH-RH/FSH-RH-Wirkung, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zubereitungen
US3971737A (en) * 1975-03-24 1976-07-27 American Home Products Corporation [2-Methyl-Ala6 ]LRH
US4018726A (en) * 1975-06-12 1977-04-19 Andrew Victor Schally [D-Phe6 ]-LH-RH and intermediates therefor
US4024121A (en) * 1976-01-27 1977-05-17 Schally Andrew Victor (Pyro)-Glu-His-Trp-D-Ser-Tyr-D-Leu-Leu-Arg-Pro-NHR and intermediates
US4010125A (en) * 1975-06-12 1977-03-01 Schally Andrew Victor [D-Trp6 ]-LH-RH and intermediates therefor
US3992530A (en) * 1975-12-08 1976-11-16 American Home Products Corporation [D-2-(1,4-Cyclohexadienyl)gly]6 -des-gly10 -lrh nonapeptide amides

Also Published As

Publication number Publication date
HU179990B (en) 1983-01-28
SE8007763L (sv) 1980-11-05
FI64139B (fi) 1983-06-30
US4100274A (en) 1978-07-11
PL104362B1 (pl) 1979-08-31
YU117277A (en) 1983-02-28
FI64139C (fi) 1983-10-10
GB1524747A (en) 1978-09-13
IE44426B1 (en) 1981-11-18
CA1101844A (en) 1981-05-26
DK149596B (da) 1986-08-04
NZ183931A (en) 1979-03-16
SE437993B (sv) 1985-03-25
IL52014A (en) 1979-11-30
PL108860B1 (en) 1980-05-31
NO822984L (no) 1977-11-14
IL52014A0 (en) 1977-07-31
NO147304C (no) 1983-03-16
IE44426L (en) 1977-11-11
NL7705130A (nl) 1977-11-15
AT379400B (de) 1985-12-27
NL970002I1 (nl) 1997-03-03
PL197889A1 (pl) 1978-02-13
YU40672B (en) 1986-04-30
BE854467A (fr) 1977-11-10
DK207977A (da) 1977-11-12
DK149596C (da) 1987-01-05
SE7705432L (sv) 1977-11-12
CH629475A5 (de) 1982-04-30
NO147304B (no) 1982-12-06
AU2468177A (en) 1978-11-02
NL970002I2 (nl) 1997-05-01
NL191793C (nl) 1996-08-02
JPS52136172A (en) 1977-11-14
DE2720245C2 (de) 1986-09-25
AU508025B2 (en) 1980-03-06
AT365562B (de) 1982-01-25
NO149586B (no) 1984-02-06
JPS6113480B2 (OSRAM) 1986-04-14
ATA217979A (de) 1981-06-15
BG60740B2 (bg) 1996-01-31
DD136738A5 (de) 1979-07-25
CS199673B2 (en) 1980-07-31
NL191793B (nl) 1996-04-01
ZA772433B (en) 1978-03-29
FI771480A7 (OSRAM) 1977-11-12
NO149586C (no) 1984-05-16
FR2351092B1 (OSRAM) 1980-02-22
FR2351092A1 (fr) 1977-12-09
DE2720245A1 (de) 1977-11-24
SE437837B (sv) 1985-03-18
SU910116A3 (ru) 1982-02-28
ATA335877A (de) 1985-05-15
CH627151A5 (OSRAM) 1981-12-31
NO771644L (no) 1977-11-14

Similar Documents

Publication Publication Date Title
ES458691A1 (es) Procedimiento para preparar polipeptidos.
ES2154627T3 (es) Estabilizacion de somatotropinas mediante la modificacion de restos de cisteina utilizando mutagenesis de localizacion dirigida o derivatizacion quimica.
ATE304020T1 (de) Parathyroidhormon-verwandthe peptidanaloge
ATE89315T1 (de) Faktor viii-analog, verfahren zu dessen herstellung und dieses enthaltende zusammensetzung.
ES531585A0 (es) Un procedimiento para preparar peptidos analogos al factor de liberacion de corticotropina
ZA202306729B (en) Novel glp-1 analogues
DK141022B (da) Fremgangsmåde til fremstilling af en antibiotisk blanding eller de enkelte komponenter betegnet teichomycin A1, teichomycin A2, teichomycin A3, antibiotisk 8327 faktor B og antibiotisk 8327 faktor C.
DK0736039T3 (da) Forbindelser med væksthormon-frigivende egenskaber
ES8405363A1 (es) Procedimiento para la obtencion de un octapeptido ciclico.
GB1329860A (en) Process for the manufacture of peptides containing cystine
ES2121804T3 (es) Nuevo interferon beta humano recombinante, procedimiento para su fabricacion y preparaciones farmaceuticas que lo contienen.
ATE10364T1 (de) Retro-inverso analoga von c-terminalen pentaund hexapeptiden der verbindung p.
ES2006725A4 (es) Mejoras en, o relacionadas con hormonas.
DK0607278T3 (da) Fremgangsmåde til forstærkning af tarmabsorption
ES2149177T3 (es) Composiciones para el tratamiento del sindrome de fatiga cronica.
NL7903871A (nl) Werkwijze ter bereiding van een prostacycline bevattend farmaceutisch preparaat, alsmede als zodanig verkregen preparaten.
DK239781A (da) Peptider der er antagonister til det luteiniserende hormon frigoerende hornon (lh-rh).
EP0352816A3 (en) Il-1alpha derivates and medicament for treating thrombocytopenia
ES8606403A1 (es) Un procedimiento de preparar peptidos.
GB849175A (en) White coating composition
RU95106486A (ru) Аналоги амилина, способы лечения сахарного диабета типа i и ii и гипергликемии, способ регулирования принятия пищи
GB615813A (en) Improvements relating to apparatus for use with molten glass
ES8501378A1 (es) Procedimiento de preparar derivados de n-cicloalcoilmetil-2 oxo-3 diaril 5-6 as triacina
GB2021581A (en) Stabilisation of PGl2 derivatives
HU911358D0 (en) Grf analogues